Lexaria Bioscience CORP 8-K filings

Lexaria Bioscience Corp. received a delisting notification from Nasdaq due to failure to meet the minimum bid price requirement, but has requested a hearing and implemented a reverse stock split to regain compliance.

Lexaria Bioscience Corp. is implementing a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enhance its ability to attract business partners.

Lexaria Bioscience Corp. received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement, initiating a 180-day compliance period.

Lexaria Bioscience Corp. announced that shareholders approved all proposals at its annual meeting, including the re-election of all director nominees and the appointment of Malone Bailey LLP as auditors.

Lexaria Bioscience Corp. completed a registered direct offering and concurrent private placement, raising approximately $3.5 million for working capital and R&D.

Lexaria Bioscience Corp. secured approximately $4.0 million in gross proceeds through a registered direct offering of common stock and a concurrent private placement of warrants to fund R&D and general corporate purposes.

Lexaria Bioscience Corp. has terminated its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, under which it sold 14,995 shares for $38,236.

Lexaria Bioscience Corp. announced a material definitive agreement to expand its Australian clinical study GLP-1-H24-4 by adding a fifth study arm investigating DehydraTECH-tirzepatide capsules and increasing subject enrollment, incurring additional costs of approximately AU$1,900,000.

Lexaria Bioscience Corp. has entered into a definitive agreement for a $2 million registered direct offering of common stock and pre-funded warrants with a single institutional investor.

Lexaria Bioscience Corp. amended its Capital on Demand Sales Agreement with JonesTrading, reducing the potential issuance of common stock to $5 million.

Lexaria Bioscience Corp. held its annual and special shareholder meeting on January 14, 2025, with all director nominees elected and other proposals approved, including executive compensation and a warrant exercise proposal.

Lexaria Bioscience Corp. has entered into a new executive management agreement with John Docherty, appointing him as President and Chief Scientific Officer, effective January 1, 2025.

Lexaria Bioscience Corp. has entered into a project agreement with Novotech for a clinical study on DehydraTECH cannabidiol in diabetes treatment.

Lexaria Bioscience Corp. will hold a joint Annual and Special Meeting of Shareholders on January 14, 2025, to seek approval for recent private placement warrants and to conduct annual business.

Lexaria Bioscience Corp. has successfully raised approximately $5 million through a registered direct offering and concurrent private placement.

Lexaria Bioscience Corp. has appointed Michael Shankman as its new Chief Financial Officer, effective October 1, 2024, replacing the interim CFO.

Lexaria Bioscience has appointed Richard Christopher as its new CEO, replacing Christopher Bunka, while also reporting progress in its clinical trials and R&D programs, particularly in GLP-1 and hypertension.

Lexaria Bioscience Corp. has entered into a sales agreement to potentially issue and sell up to $20 million of its common stock through an at-the-market offering.

Lexaria Bioscience's DehydraTECH technology demonstrates positive interim results in an animal study, showing potential for enhanced delivery of GLP-1 drugs and CBD for diabetes treatment.

Lexaria Bioscience Corp. has entered into a warrant exercise agreement, securing approximately $4.7 million in gross proceeds through the full exercise of existing warrants and issuing new warrants to the investor.

Lexaria Bioscience Corp. held its annual shareholder meeting on April 23, 2024, where all director nominees were elected and other proposals were approved.

Lexaria Bioscience Corp. has amended its licensing agreement with Premier Anti-Aging, transitioning from an exclusive perpetual license to a non-exclusive license with reduced fees and a term ending August 31, 2025.

Lexaria Bioscience Corp. has appointed Nelson Cabatuan as its new Chief Financial Officer, effective March 14, 2024, replacing outsourced services.

Lexaria Bioscience Corp. has received a Study May Proceed letter from the FDA, allowing them to move forward with their Phase 1b hypertension clinical trial.

Lexaria Bioscience Corp. has successfully completed a $3.6 million registered direct offering, alongside a concurrent private placement of warrants.

Lexaria Bioscience has submitted an Investigational New Drug application to the FDA for a Phase 1b clinical trial of its DehydraTECH-CBD technology in hypertension patients.

Lexaria Bioscience's CEO letter details the company's 2023 achievements, challenges in capital markets, and a strategic shift towards GLP-1 research in 2024.